Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab

Addition of investigational antibody cusatuzumab to robust oncology pipeline reflects Janssen's commitment to advance innovative therapies for blood cancers where unmet medical needs remain UG, Switzerland, December 3, 2018 -- (Healthcare Sales & Market... Biopharmaceuticals, Oncology, Licensing Cilag, argenx BVBA, argenx SE, cusatuzumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news